**Summary**
Avingtrans plc, a UK-based company specializing in critical components and systems for energy, medical, and industrial sectors, announced that its subsidiary Adaptix Limited has received FDA 510(k) clearance for its orthopaedic 3D imaging product, the Adaptix Ortho350. This compact, mobile, low-dose Digital Tomosynthesis (DT) system is designed for point-of-care use, offering fast, affordable, and high-quality 3D X-ray imaging for upper and lower extremity diagnostics. The clearance enables Adaptix to enter the U.S. human healthcare imaging market, marking a significant milestone in its mission to revolutionize radiology. The Ortho350 delivers superior image clarity compared to 2D X-ray systems while reducing radiation exposure, improving diagnostic accuracy, and enhancing patient outcomes. Adaptix has already commercialized similar technology in veterinary and industrial markets, and this FDA approval validates the technologys commercial potential. Company executives expressed excitement about the strong interest from healthcare providers and the systems potential impact on primary care, intensive care, and emergency departments.